Durvalumab vs Midazolam

Durvalumab vs Midazolam: Overview

This comparison examines the pharmacological differences between Durvalumab and Midazolam.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Midazolam: Ultra-short-acting benzodiazepine GABA-A receptor positive allosteric modulator.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Midazolam — 1.5-2.5 hours.

Chemical Properties

Molecular Formula: Midazolam — C18H13ClFN3.

Molecular Weight: Midazolam — 325.7670 g/mol.

Type: Durvalumab — Antibody; Midazolam — Small molecule.